{
    "Symbol": "GSK",
    "AssetType": "Common Stock",
    "Name": "GlaxoSmithKline PLC ADR",
    "Description": "GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.",
    "CIK": "1131399",
    "Exchange": "NYSE",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "PHARMACEUTICAL PREPARATIONS",
    "Address": "980 GREAT WEST ROAD, BRENTFORD MIDDLESEX, GB",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2024-06-30",
    "MarketCapitalization": "80844587000",
    "EBITDA": "10063000000",
    "PERatio": "13.67",
    "PEGRatio": "1.087",
    "BookValue": "3.523",
    "DividendPerShare": "0.6",
    "DividendYield": "0.0376",
    "EPS": "2.9",
    "RevenuePerShareTTM": "15.47",
    "ProfitMargin": "0.128",
    "OperatingMarginTTM": "0.281",
    "ReturnOnAssetsTTM": "0.0858",
    "ReturnOnEquityTTM": "0.333",
    "RevenueTTM": "31446000000",
    "GrossProfitTTM": "19917000000",
    "DilutedEPSTTM": "2.9",
    "QuarterlyEarningsGrowthYOY": "-0.282",
    "QuarterlyRevenueGrowthYOY": "0.098",
    "AnalystTargetPrice": "45.9",
    "AnalystRatingStrongBuy": "2",
    "AnalystRatingBuy": "1",
    "AnalystRatingHold": "4",
    "AnalystRatingSell": "1",
    "AnalystRatingStrongSell": "0",
    "TrailingPE": "13.67",
    "ForwardPE": "10.32",
    "PriceToSalesRatioTTM": "2.751",
    "PriceToBookRatio": "4.965",
    "EVToRevenue": "3.319",
    "EVToEBITDA": "11.08",
    "Beta": "0.296",
    "52WeekHigh": "45.8",
    "52WeekLow": "32.74",
    "50DayMovingAverage": "40.57",
    "200DayMovingAverage": "39.8",
    "SharesOutstanding": "2039470000",
    "DividendDate": "2024-07-11",
    "ExDividendDate": "2024-05-16"
}